PDF下载 ( 171 KB)
The effect of S-adenosyl-methionine treatment on drug-induced liver injury
-
摘要: 目的评价不同剂量S-腺苷蛋氨酸治疗胆汁淤积型和混合型药物性肝损害的疗效和安全性。方法 66例胆汁淤积型和混合型药物性肝损害患者,分为对照组、治疗1组和治疗2组,每组22例,对照组给予常规基础保肝治疗外加用熊去氧胆酸和茵栀黄颗粒,治疗组除上述治疗外,同时加以S-腺苷蛋氨酸治疗。治疗1组应用S-腺苷蛋氨酸1g,1次/d,连续治疗4周;治疗2组以S-腺苷蛋氨酸2g,1次/d,连续治疗4周。监测各项肝功能指标。结果与对照组相比,治疗组总胆红素（TBil）、丙氨酸氨基转移酶（ALT）明显下降,差异有统计学意义（P<0.05）。治疗2组疗效在降低TBil、ALT方面明显优于治疗1组,差异有统计学意义（P<0.01）。结论胆汁淤积型和混合型药物性肝损害,给予S-腺苷蛋氨酸较常规保肝治疗效果明显,无不良反应,且大剂量疗效更为显著。Abstract: Objective To evaluate the therapeutic efficacy and safety of different dose S-adenosyl-L-methionine on drug-induced cholestasis liver injury and mixed liver injury.Methods a total of 66 patients suffered from drug-induced cholestasis liver injury and mixed liver injury were randomly divided into treatment group and control group.Furthermore, the treatment group was divided into 2 groups as treatment 1 group and treatment 2 group.The control group was treated with common therapy, while the treatment 1 group was treated with S-adenosyl-L-methionin up to 1 g/d as well as the treatment 2 group was treated with S-adenosyl-methionin up to 2 g/d.After 4 weeks of treatment, liver function was measured.Results The level of total bilirubin and alanine transaminase significantly decreased in the treatment group than the control group (P < 0.05) .Moreover, no adverse reactions were observed.Total bilirubin and alanine transarninase significantly decreased in treatment 2 group compared to treatment 1 group (P < 0.01) .Conclusion The therapeutic efficacy and safety of large dose S-adenosyl-L-methionin in treating drug-induced cholestasis liver injury and mixed liver injury is better compared to the common therapy.
-
Key words:
- S-adenosyl-methionine /
- hepatitis
-
[1]Bénichou C.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatology, 1990, 11 (2) ∶272-276. [2]Danan G, Benichou C.Causality assessment of adverse reactions to drugs-I.A novel method based on the conclusions of international consensus meetings application to drug-induced liver injuries[J].J Clin Epidemiol, 1993, 46 (11) ∶1323-1330. [3]Ribalta J, Reyes H, Gonzalez MC.S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy:a randomized, double-blind, placebo-controlled study with negative results[J].Hepatology, 1991, 13 (6) ∶1084-1089. [4]Bogdanos DP, Dalekos GN.Enzymes as target antigens of liver specific autoimmunity:the case of cytochromes P450s[J].Curr Med Chem, 2008, 15 (22) ∶2285-2292. [5]Russmann S, Kullak-Ublick GA, Grattagliano I.Current concepts of mechanisms in drug-induced hepatotoxicity[J].Curr Med Chem, 2009, 16 (23) ∶3041-3053. [6]Murray KF, Hadzic N, Wirth S.Drug-related hepatotoxicity and acute liver failure[J].J Pediatr Gastroenterol Nutr, 2008, 47 (4) ∶395-405. [7]Uetrecht J.Immunoallergic drug-induced liver injury in humans[J].Semin Liver Dis, 2009, 29 (4) ∶383-392. [8]Andrade RJ, Robles M, Ulzurrun E.Drug-induced liver injury:insights from genetic studies[J].Pharmacogenomics, 2009, 10 (9) ∶1467-1487. [9]Tarantino G, Di Minno MN, Capone D.Drug-induced liver injury:is it somehow foreseeable[J].World J Gastroenterol, 2009, 15 (23) ∶2817-2833. [10]Bliven EE, Podewils LJ.The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection[J].Int J Tuberc Lung Dis, 2009, 13 (9) ∶1054-1060. [11]Anderson GD.Gender differences in pharmacological response[J].Int Rev Neurobiol, 2008, 83∶1-10. [12]Tajiri K, Shimizu Y.Practical guidelines for diagnosis and early management of drug-induced liver injury[J].World J Gastroenterol, 2008, 14 (44) ∶6774-6785. [13]王雪明, 李楠, 魏荣.腺苷蛋氨酸治疗药物性肝损害疗效与血液中GSH变化关系[J].中国基层医药, 2002, 9 (6) ∶497-498. -
本文二维码
计量
- 文章访问数: 263
- HTML全文浏览量: 23
- PDF下载量: 159
- 被引次数: 0
下载:
